Medications used to treat Parkinson's disease and the risk of gambling

European Journal of Neurology

Volumn 15, Issue 4, 2008, Pages 350-354

  Imamura, A ^a   Geda, Y E ^b,c   Slowinski, J ^a   Wszolek, Z K ^a   Brown, L A ^a   Uitti, R J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

Gambling; Hypothesis testing; Parkinson's disease; Pramipexole

Indexed keywords

BROMOCRIPTINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; MEDICAL RECORD; MONOTHERAPY; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; GAMBLING; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; RETROSPECTIVE STUDIES; REVIEW LITERATURE AS TOPIC; RISK;

EID: 41049085788     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02081.x     Document Type: Article

References (24)

1. Cummings JL. Frontal-subcortical circuits and human behavior. Archives of Neurology 1993 50 : 873 880.
2. Breo DL. In treating the pathological gambler, MDs must overcome the attitude, 'why bother?' The Journal of the American Medical Association 1989 262 : 2599 2600, 2603, 2606.
3. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006 67 : 1254 1257.
4. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Movement Disorders 2006 21 : 2068 2072.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington : American Psychiatric Association, 2000.
6. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Archives of Neurology 2005 62 : 1377 1381.
7. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. Journal of Neurology, Neurosurgery, and Psychiatry 2000 68 : 423 428.
8. Fahn S, Alton R, UPDRS Development Committee. Unified Parkinson's disease rating scale. In : Fahn S, Marsden C, Caline D, Goldstein M eds. Recent Development in Parkinson's Disease. Florham Park : McMillan Healthcare Information, 1987 : 153 163.
9. Hoen M, Yahr M. Parkinsonism: onset progression and mortality. Neurology 1967 17 : 427 442.
10. Krause M, Fogel W, Heck A, et al. Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus. Journal of Neurology, Neurosurgery, and Psychiatry 2001 70 : 464 470.
11. Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999 53 : 85 90.
12. Uitti RJ, Baba Y, Wszolek ZK, Putzke DJ. Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Parkinsonism & Related Disorders 2005 11 : 139 145.
13. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Archives of Neurology 1999 56 : 33 39.
14. Schlesselman J. Case-Control Studies. New York : Oxford University Press, 1982.
15. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003 61 : 422 423.
16. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Movement Disorders 2004 19 : 433 437.
17. Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depression and Anxiety 2000 11 : 185 186.
18. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006 66 : 1750 1752.
19. Imamura A, Uitti RJ, Wszolek ZK. Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism & Related Disorders 2006 12 : 506 8.
20. Grosset KA, Macphee G, Pal G, et al. Dopamine agonists and pathological gambling. Parkinsonism & Related Disorders 2007 13 : 259.
21. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? Journal of Neurology, Neurosurgery, and Psychiatry 2004 75 : 637 639.
22. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Movement Disorders 2000 15 : 869 872.
23. Szklo M, Nieto F. Epidemiology: Beyond the Basics. Gaithersburg : Aspen Publishers, Inc., 2000.
24. Piercey MF. Pharmacology of pramipexole, a dopamine D-3 preferring agonist useful for the treatment of Parkinson's disease. Clinical Neuropharmacology 1998 21 : 141 151.